In a mouse model of rheumatoid arthritis, GILZ expression in mesenchymal stem cells (MSCs) is required for therapeutic effectiveness of MSCs in arthritis (68) and inhibition of transferred- Th-1, and Th-17 cells in immunized mice (70). Here, TSC22D3 is linked to arthritic joint disease.